Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : DNDi
Deal Size : Undisclosed
Deal Type : Collaboration
Details : MoU aims to bring together DNDi’s expertise in NTDs with the scientific, technical and commercial capabilities of APSL and Dr. Reddy’s. The parties will explore a potential collaboration to develop and market novel and improved drugs for the treatmen...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 30, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : DNDi
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Curcuminoid,Ellagic acid,Gingerol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : AIIMS
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : After ten days of treatment with Phytorelief along with standard management, 83% of Covid-19 patients, with mild or moderate symptoms, turned negative in a trial conduct in AIIMS Patna.
Product Name : Phytorelief-CC
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 06, 2021
Lead Product(s) : Curcuminoid,Ellagic acid,Gingerol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : AIIMS
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BCG Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Serum Institute Seeks Nod For Adult TB Vaccine
Details : The vaccine, TUBERVAC-rBCG can be administered to children and adults both. Once DCGI approves Serum Institute's TB vaccine, the National Technical Advisory Group on Immunisation (NTAGI) will decide on its introduction.
Product Name : TUBERVAC-rBCG
Product Type : Vaccine
Upfront Cash : Inapplicable
December 13, 2022
Lead Product(s) : BCG Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Indian Institute of Science
Deal Size : Inapplicable
Deal Type : Inapplicable
India's 'Warm' Vaccine Candidate Effective Against Delta, Omicron Variants in Mice: Study
Details : A heat-stable COVID-19 vaccine that is being developed in India and does not need cold chain storage has generated strong antibody response against coronavirus variants, including Delta and Omicron, according to a study on mice.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
April 16, 2022
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Indian Institute of Science
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 2-Deoxy-D-Glucose
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Lee Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
CSIR-IICT Licenses Process Knowhow for Synthesis of 2-Deoxy-D-Glucose to Lee Pharma Ltd.
Details : Indian Institute of Chemical Technology, (IICT) and Lee Pharma have entered into a non-exclusive licensing agreement for the synthesis of 2-Deoxy-D-Glucose (2-DG). Lee Pharma would file the application for getting the approval from DCGI and will manufact...
Product Name : 2-DG
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 06, 2021
Lead Product(s) : 2-Deoxy-D-Glucose
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Lee Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Baricitinib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : University of Oxford
Deal Size : Inapplicable
Deal Type : Inapplicable
Call for Expression of Intent to Participate as a Study Site for India-UK RECOVERY
Details : Baricitinib will only be included in the randomisation of women of child-bearing potential if they have had a negative pregnancy test since admission.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 14, 2021
Lead Product(s) : Baricitinib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : University of Oxford
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Baricitinib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Natco Files for Patent Waiver Rights for Baricitinib
Details : Natco Pharma has filed for a waiver of patent rights to manufacture rheumatoid arthritis drug Baricitinib. The CL, if granted, will help in improving the accessibility and affordability of the drug, bringing its price down substantially.
Product Name : Olumiant
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 05, 2021
Lead Product(s) : Baricitinib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Covimabs
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Covid-19: Zydus Seeks DCGI Nod to Undertake Clinical Trials for Monoclonal Antibodies Cocktail
Details : ZRC-3308 (Covimabs) is a cocktail of two anti-SARS-CoV-2 monoclonal antibodies that target the SARS-CoV-2 spike protein to combat mild COVID 19. Two of these products comprising of two mAbs binding to two different epitopes on spike protein of SARS-CoV-2...
Product Name : ZRC-3308
Product Type : Antibody
Upfront Cash : Inapplicable
May 27, 2021
Lead Product(s) : Covimabs
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NVX-COV2373,Matrix-M
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Novavax
Deal Size : Inapplicable
Deal Type : Inapplicable
India's Serum Applies to Conduct Local Trial for Novavax Vaccine
Details : The Serum Institute of India has applied to local authorities to conduct a small domestic trial of Novavax Inc’s COVID-19 vaccine, which was found to be 89.3% effective in a UK trial. Novavax’s COVID-19 vaccine shown to be nearly 90% effective in UK ...
Product Name : Covovax
Product Type : Vaccine
Upfront Cash : Inapplicable
January 29, 2021
Lead Product(s) : NVX-COV2373,Matrix-M
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Novavax
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Active Virosome Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : The Union Science and Technology Ministry of India
Deal Size : Undisclosed
Deal Type : Funding
Pune Firm First in India to Get Govt Funding for COVID-19 Vaccine
Details : The Union science and technology ministry will fund Seagull Biosolutions to develop a vaccine for Covid-19 which is expected to enter phase-1 trial in 18-20 months.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
December 04, 2020
Lead Product(s) : Active Virosome Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : The Union Science and Technology Ministry of India
Deal Size : Undisclosed
Deal Type : Funding